ClinicaliQ Trial Snapshot
- A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) — Active Not Recruiting • Phase III • Gastroenterology • NCT05500222.
- A drug called resmetirom tested to see if it prevents liver disease progression in patients with advanced fatty liver cirrhosis.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will determine the effect of oral 80 mg resmetirom administered once daily on participants with well-compensated non-alcoholic steatohepatitis (NASH) cirrhosis by measuring the time to experiencing a Composite Clinical Outcome event. Conditions: NASH, Cirrhosis, Liver Interventions: Resmetirom, Placebo Lead Sponsor: Madrigal Pharmaceuticals, Inc. Planned Enrollment: 845 participants